All In Biotech

Drug Trial Radar · NCT01797978

Methylene Blue in Severe Sepsis and Septic Shock

Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded

Last checked: Nov 20, 2026Latest source record: Nov 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

354

Planned (sponsor's estimate)

Start

Feb 2013

Primary completion

Jan 2016

Study completion Mar 2017

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.

Conditions

  • Severe Sepsis
  • Septic Shock

Interventions

  • Intravenous methylene blue administrationDrug

    Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28 day mortalityTime frame: within 28 days of diagnosis

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • SMG - SNU Boramae Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Kyeongi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.